To include your compound in the COVID-19 Resource Center, submit it here.

Public financing roundup: Kadmon, TherapeuticsMD, GTx, Newron

On Sept. 26, several biotechs announced public financing, including follow-ons from Kadmon Holdings Inc. (NYSE:KDMN) and TherapeuticsMD Inc. (NYSE-M:TXMD).

Kadmon raised $80 million through the sale of 26.8 million shares at $3 in a bumped-up follow-on and a registered direct offering. The follow-on was underwritten by Jefferies,

Read the full 467 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers